Vitamin D is one of the most requested single-nutrient ingredients from brands abroad, usually alongside calcium or as a stand-alone softgel. It is also one of the most studied nutrients in modern medicine, which means there is a large and sometimes contradictory literature behind a very small, cheap ingredient.
This guide is for brand owners planning a Japan-made vitamin D product. It covers what the largest trials actually found, how Japan’s Foods with Nutrient Function Claims system frames vitamin D, where the evidence is genuinely stronger, and what to fix before asking for a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a vitamin D product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
The largest randomised trial of vitamin D ever run found no reduction in cancer or major cardiovascular events in the general adult population, while a separate meta-analysis found a real benefit against respiratory infection, concentrated in people who were vitamin D deficient to begin with.
| Study | Design | Reported result |
|---|---|---|
| VITAL trial, New England Journal of Medicine 2019 (PMID 30415629) | Randomised, placebo-controlled trial; vitamin D3 2,000 IU/day for a median 5.3 years; 25,871 US adults (men ≥50, women ≥55) | No reduction in invasive cancer (hazard ratio 0.96, 95% CI 0.88–1.06) or major cardiovascular events (hazard ratio 0.97, 95% CI 0.85–1.12) versus placebo; no excess of hypercalcaemia or other adverse events |
| Individual-participant-data meta-analysis, BMJ 2017 (PMID 28202713) | 25 randomised, double-blind, placebo-controlled trials; 10,933 participants aged 0–95 | Vitamin D reduced acute respiratory tract infection overall (adjusted odds ratio 0.88, 95% CI 0.81–0.96); the effect was much larger in people with baseline 25-hydroxyvitamin D below 25 nmol/L (adjusted odds ratio 0.30, 95% CI 0.17–0.53) than in those at or above that level (adjusted odds ratio 0.75, 95% CI 0.60–0.95); daily or weekly dosing worked, single large bolus doses did not |
| Umbrella review of meta-analyses, Journal of Clinical Endocrinology & Metabolism 2022 (PMID 34687206) | Review of 19 systematic reviews/meta-analyses on vitamin D alone and 13 on vitamin D plus calcium, for fracture risk in adults | No fracture-risk reduction was seen in reviews restricted to community-dwelling adults, or in any review of vitamin D supplementation alone versus placebo; vitamin D plus calcium reduced hip and any-fracture risk in most reviews, an effect the authors linked mainly to institutionalised populations |
Three points worth holding onto:
- The headline trial is a null result for two major end points. VITAL was designed and powered to detect a reduction in cancer and cardiovascular events in generally healthy, mostly vitamin-D-sufficient US adults. It did not find one. That does not disprove every possible benefit of vitamin D, but it does mean broad disease-prevention claims are not supported by the best available evidence.
- The respiratory-infection benefit is concentrated in the deficient. The BMJ meta-analysis is genuine positive evidence, but its strongest effect sat in people who started deficient and took daily or weekly doses, not people who were already replete or who took one large periodic dose.
- Fracture evidence points to calcium plus vitamin D, not vitamin D alone, and mainly in institutionalised adults. A 2022 umbrella review found no consistent benefit from vitamin D by itself in community-dwelling adults.
Checked against the published abstracts on 25 September 2026.
What Japanese products say
Japan’s Foods with Nutrient Function Claims system fixes both the wording and the daily amount for vitamin D, and neither can be adjusted by the seller.
Under this system (栄養機能食品), a business can label a food with a nutrient function claim without individual government review, provided the notified daily serving amount falls within a fixed range and the claim uses only the wording the Consumer Affairs Agency (CAA) has set. For vitamin D, the CAA’s Food Labeling Standards (食品表示基準 別表第11) set the following, as published in the CAA’s April 2025 reference document:
- Notified daily amount: 1.65 to 5.0 micrograms. This is a labeling range for how much the product may be notified to contain per day — it is not a medical safety ceiling, and it is far below the separate tolerable upper intake level used in nutrition science (see below).
- Mandatory function claim (verbatim, cannot be reworded): “Vitamin D is a nutrient that promotes the absorption of calcium in the intestine and helps in the formation of bone.”
- Mandatory caution statement (verbatim, shared with several other vitamins in this system): “This product does not cure disease or further promote health through excessive intake. Follow the daily recommended amount.”
- Standard disclosure: “Unlike Foods for Specified Health Uses, this product has not been individually reviewed by the Commissioner of the Consumer Affairs Agency.”
Two lessons for a brand abroad:
- This is a self-certification system with fixed wording, not a scientific endorsement your brand can expand on. The notifying business simply confirms the amount sits in range and uses the set sentences. It says nothing about cancer, heart disease, infection or any outcome beyond calcium absorption and bone formation.
- A Japanese Foods with Nutrient Function Claims notification is a Japanese labeling mechanism. It has no legal standing outside Japan. Your label abroad follows your own market’s rules, including the EU’s separately authorised claims for vitamin D (see the wording section below).
💬 Need an evidence summary for your regulatory adviser that separates Japan’s fixed wording from the international trial evidence? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe vitamin D by its role in calcium absorption and bone, not by disease outcomes a null trial did not find.
| Safer wording | Wording to avoid |
|---|---|
| ”Contributes to normal calcium absorption and bone maintenance" | "Prevents cancer”, “protects the heart”, or any claim tied to the VITAL trial’s null primary end points |
| ”Studied for respiratory infection risk in people with low vitamin D status” | Blanket “boosts immunity” or “prevents colds” claims that ignore the deficiency-dependent result |
| ”Contains [amount] mcg/IU vitamin D3 per serving” | Any wording that implies the amount treats or reverses a diagnosed deficiency — that is a medical, not a food, claim |
In the EU, Regulation (EU) No 432/2012 authorises specific vitamin D wordings such as “Vitamin D contributes to normal absorption/utilisation of calcium and phosphorus,” “Vitamin D contributes to the maintenance of normal bones,” and “Vitamin D contributes to the normal function of the immune system,” each subject to the regulation’s own minimum-content conditions. Authorised EU wording must be used exactly as set and only where your product meets those conditions — confirm current status in the EU Register before you rely on it.
How vitamin D is formulated
Vitamin D is fat-soluble and active in microgram amounts, so the main formulation questions are the oil carrier, the form (D2 or D3) and whether the amount matches a notified or authorised claim.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Softgel (oil suspension) | Matches vitamin D’s fat solubility; simple, stable | Gelatin source for dietary suitability |
| Hard tablet or capsule with oil-coated powder | Combines easily with calcium, magnesium or other minerals | Oil-coating technology affects stability and cost |
| Oral drops | Common for very small servings or paediatric-style formats | Precise dosing device; light and oxygen protection |
Decisions that shape the specification:
- D2 or D3. Vitamin D3 (cholecalciferol) is the form used in the VITAL trial and most recent human research; vitamin D2 (ergocalciferol) is also used, including in some vegan-suitable material. Confirm which your target market expects and which studies you intend to reference.
- Amount per serving. If you plan to reference Japan’s Foods with Nutrient Function Claims wording, the notified amount must sit within 1.65–5.0 mcg/day. If you plan to reference the VITAL trial or other international research, note that those doses (for example 2,000 IU/50 mcg/day in VITAL) sit well above the Japanese labeling range and would need their own market’s regulatory route.
- Source and dietary suitability. Vitamin D3 for foods is commonly derived from lanolin (sheep’s wool grease) or produced by other methods; ask the supplier for the source, as it affects whether the product can be described as vegan or vegetarian.
- Companion ingredients. Calcium, magnesium and vitamin K2 are common partners. Each needs its own check against Japanese food law and your market’s rules, and a combined formula changes the notified-amount calculation if you use Japan’s function-claims system.
- Packaging and stability. Vitamin D is sensitive to light and oxidation over long shelf lives; ask the factory how the formula and packaging protect potency to the end of shelf life, not only at manufacture.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Vitamin D itself is a routine food and supplement ingredient in Japan. The risk in a vitamin D formula usually sits in companion ingredients — some minerals and botanicals added for a “bone” or “immunity” story are treated differently under Japanese food law than in other markets. See the Japan-made supplement OEM page, and compare with our collagen peptide and hyaluronic acid guides for other examples of checking a combined formula before committing to a spec.
Before you ask for a quotation
A factory can quote accurately once the form, the amount, the companions and the packaging are fixed.
- D2 or D3, and the raw material source
- Amount per serving, and whether it targets Japan’s notified range or another market’s rules
- Dosage form (softgel, tablet, drops)
- Companion ingredients and their amounts
- Packaging and expected shelf life
- Countries you will sell in, and first order and annual volume
💬 Ready to design a Japan-made vitamin D product? Send us the concept — form, amount, companion ingredients and the countries you will sell in.
Frequently asked questions
1. Does vitamin D prevent cancer or heart disease?
The largest randomised trial to test this, VITAL (25,871 US adults, 2,000 IU/day for a median 5.3 years), found no reduction in invasive cancer or major cardiovascular events compared with placebo. Describe vitamin D by its studied role in calcium absorption and bone, not as disease prevention.
2. Is there any solid evidence for vitamin D and infections?
Yes. A 2017 individual-participant-data meta-analysis in BMJ (10,933 participants, 25 trials) found a real reduction in acute respiratory tract infections, with the strongest effect in people who were vitamin D deficient at baseline and took daily or weekly doses rather than large periodic doses.
3. What amount does Japan’s Foods with Nutrient Function Claims system allow for vitamin D?
A notified daily amount of 1.65 to 5.0 micrograms, paired with fixed wording the Consumer Affairs Agency has set. This is a labeling range, not a medical safety limit.
4. How much vitamin D is considered unsafe?
The US National Institutes of Health’s Office of Dietary Supplements lists a Tolerable Upper Intake Level of 25–100 mcg (1,000–4,000 IU) per day, depending on age. This is a separate figure from Japan’s much lower labeling range for Foods with Nutrient Function Claims, which governs what a product notification may state, not the outer safety limit.
5. Does vitamin D reduce fractures or falls?
A 2022 umbrella review of meta-analyses found no consistent fracture reduction from vitamin D supplementation alone in community-dwelling adults. Vitamin D combined with calcium showed a benefit in most reviews, an effect linked mainly to institutionalised populations rather than the general public.
Sources: “Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease”, Manson JE et al, New England Journal of Medicine 2019;380(1):33-44 (PMID 30415629); “Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data”, Martineau AR et al, BMJ 2017;356:i6583 (PMID 28202713); “Vitamin D Supplementation and Fractures in Adults: A Systematic Umbrella Review of Meta-Analyses of Controlled Trials”, Chakhtoura M et al, Journal of Clinical Endocrinology & Metabolism 2022 (PMID 34687206); NIH Office of Dietary Supplements, Vitamin D Health Professional Fact Sheet; Commission Regulation (EU) No 432/2012, Annex (vitamin D entries); Consumer Affairs Agency, “Foods with Nutrient Function Claims” reference document, April 2025 (食品表示基準 別表第11). Checked on 25 September 2026.